ClinVar Miner

Submissions for variant NM_004985.5(KRAS):c.101C>G (p.Pro34Arg)

dbSNP: rs104894366
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000211723 SCV000061924 likely pathogenic Noonan syndrome; Cardio-facio-cutaneous syndrome 2015-08-21 criteria provided, single submitter clinical testing The p.Pro34Arg in KRAS variant has been reported 1 adolescent with clinical feat ures of Cardio-facio-cutaneous syndrome as a de novo occurrence (Schubbert 2006) and by our laboratory in 1 child with clinical features of Noonan syndrome (LMM unpublished data). It was absent from large population studies. In vitro functi onal studies provide evidence that the p.Pro34Arg may impact protein function (S tone 1993, Schubbert 2007, Gremer 2010). However, these types of assays may not accurately represent biological function. In summary, although additional studie s are required to fully establish its clinical significance, the p.Pro34Arg vari ant is likely pathogenic.
Molecular Diagnostics Lab, Nemours Children's Health, Delaware RCV000207495 SCV000263050 pathogenic not provided 2015-07-20 criteria provided, single submitter clinical testing
GeneDx RCV000207495 SCV000329384 pathogenic not provided 2022-06-14 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect through constitutive phosphorylation of MEK, ERK, AKT and S6; supporting a gain of function mechanism (Gremer et al., 2011; Schubbert et al., 2007); Not observed at significant frequency in large population cohorts (gnomAD); Missense variants in this gene are often considered pathogenic (HGMD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; This variant is associated with the following publications: (PMID: 28958387, 20949621, 24803665, 31216405, 17875937, 16474405)
Baylor Genetics RCV000850569 SCV000992785 pathogenic Noonan syndrome 3; Autoimmune lymphoproliferative syndrome type 4; Acute myeloid leukemia; Cardiofaciocutaneous syndrome 2 2017-12-31 criteria provided, single submitter clinical testing
Invitae RCV001851825 SCV002159858 pathogenic RASopathy 2021-12-22 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro34 amino acid residue in KRAS. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17056636). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects KRAS function (PMID: 20949621). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KRAS protein function. ClinVar contains an entry for this variant (Variation ID: 12590). This missense change has been observed in individual(s) with cardio-facio-cutaneous syndrome (PMID: 16474405). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 34 of the KRAS protein (p.Pro34Arg).
OMIM RCV000043674 SCV000033668 pathogenic Cardiofaciocutaneous syndrome 2 2006-03-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.